REG - Medpal AI PLC - MedPal Enters At-Home Blood Testing Market

Medpal AIAnnouncement

Yesterday 08:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260320:nRST4665Xa&default-theme=true

RNS Number : 4665X  Medpal AI PLC  20 March 2026

20 March 2026

MedPal AI plc

("MedPal AI" or the "Company")

MedPal Enters At-Home Blood Testing Market

 

MedPal AI (AIM: MPAL, FRA: Z1N), the UK digital health and AI company, today
announces its entry into the at-home blood testing market with the launch of
the MedPal weight loss blood test.

 

Designed for users of GLP-1 medications such as Mounjaro and Wegovy, who
require regular blood tests to monitor their health, the clinically validated
kit is the first in a diagnostics range planned for introduction by the
Company through the course of 2026. It adds a third revenue stream alongside
the Company's AI wellness app and automated pharmacy operations at
MedPal.clinic.

 

Samples are collected at home using the virtually painless Tasso+ device and
analysed by a UKAS-accredited laboratory (ISO 15189). The results are
delivered directly into the MedPal app within 48 hours, combining with data
from over 100 wearables powered by Google's Vertex AI to create comprehensive
health profiles and personalised recommendations.

 

Initially the kits are to be introduced exclusively to existing MedPal app
users.  A broader range of tests - covering general health, men's health,
women's hormonal health and wellness panels - will roll out throughout 2026.

 

Jason Drummond, CEO & Founder of MedPal AI commented

 

"Blood testing is the missing layer in consumer health. By combining
wearables, blood biomarkers, AI insights and pharmacy fulfilment in one
ecosystem, we can now take users seamlessly from insight to diagnosis to
treatment.".

 

Enquiries:

 MedPal AI plc

 Jason Drummond, Chief Executive Officer     Via Square1 Consulting

 Cairn Financial Advisers LLP                +44 (0) 20 7213 0880

 Louise O'Driscoll/Jo Turner

 Clear Capital Markets Limited               +44 (0) 20 3869 6080

 Bob Roberts

 Square1 Consulting                          +44 (0) 20 7929 5599

 David Bick                                  +44 (0) 7831 381201

 

 

 

About MedPal AI

MedPal AI is a UK-based digital health company specialising in AI-driven
wellness management. Its core app aggregates data from over 100 wearables and
health apps (e.g. Apple Health, Fitbit, Garmin) into a unified profile,
offering non-clinical, personalised lifestyle guidance through its AI wellness
coach. The Company is also developing conversational AI to provide
voice-based, real-time health insights, alerts, and recommendations.

Through its wholly owned subsidiary MedPal Limited, the Company operates a
24/7 AI-powered automated pharmacy distribution centre, providing nationwide
NHS and private prescription services. The facility leverages advanced robotic
dispensing technology integrated with AI triage to deliver rapid,
cost-effective medication fulfilment with same-day and next-day delivery
capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for
a limited time, grant exclusive, zero-cost access to the MedPal AI app across
Epassi's network of 11M+ employees at major firms like Siemens and Volvo.
Beyond consumers, MedPal AI plans to expand via B2B licensing to healthcare
providers, businesses, and insurers, with potential use in insurance-linked
wellness programs to reduce premiums and drive new revenue through
institutional partnerships. The Company also has a partnership agreement with
Independent Gyms Ltd.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or
anticipated future events and anticipated results that are forward-looking in
nature and, as a result, are subject to certain risks and uncertainties, such
as general economic, market and business conditions, competition for qualified
staff, the regulatory process and actions, technical issues, new legislation,
uncertainties resulting from potential delays or changes in plans,
uncertainties resulting from working in a new political jurisdiction,
uncertainties regarding the results of exploration, uncertainties regarding
the timing and granting of prospecting rights, uncertainties regarding the
timing and granting of regulatory and other third party consents and
approvals, uncertainties regarding the Company's or any third party's ability
to execute and implement future plans, and the occurrence of unexpected
events.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRDBLBLQXLEBBX



            Copyright 2019 Regulatory News Service, all rights reserved